Helmsley Charitable Trust Awards $52 Million to Support the Global Platform for the Prevention of Autoimmune Diabetes
Release Date:
11/06/2017
... (GPPAD; “gee-pad”) and its first trial – the Primary Oral Insulin Trial (POInT). Leading GPPAD will be ... of T1D, provides a multicenter platform for both large and small T1D primary...
